The use of protease inhibitor in multiple myeloma patients who refractory to bortezomib

The phase Ib study of the use of protease inhibitor, (lopinavir/ritonavir), in combination with bortezomib and dexamethasone in multiple myeloma patients who refractory to bortezomib

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211027004

Enrollment

Registered

2021-10-27

Start date

2024-03-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or relapsed and refractory multiple myeloma Prior treated with bortezomib Multiple myeloma Protease inhibitor Relapsed multiple myeloma Relapsed and refractory multiple myeloma

Interventions

Protease inhibitor in combination with bortezomib and dexamethasone

Experimental Drug

Protease inhibitor group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Relapsed or relapsed and refractory multiple myeloma Prior treated with bortezomib Measurable disease: M-protein > 0.5 g/dL

Exclusion criteria

Exclusion criteria: Severe allergy to protease inhibitor Requiring administration strong CYP3A4 metabolized drugs active infection peripheral neuropathy more than grade 2

Design outcomes

Primary

Measure	Time frame
Safety 1 year Percentage	—

Secondary

Measure	Time frame
response rate 12 months Percentage	—

Countries

Thailand

Contacts

Public ContactChutima Kunacheewa

Divivsion of Hamtology, Department of Medicine, Siriraj Hospital, Mahidol university

chutima.kua@mahidol.ac.th024194449

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026